



[← Go to search](#)

ASR-2025-00322

Nordsjaellands Hospital

IMP: Furosemide
Submitted: 28/01/2025

MSC
DK, NL,
SE

saMS

ASR
reporting
period

Submitted

01/01/2024-28/01/2025
-
31/12/2024

ASR
Submission Assessment
() ()

SPONSOR DETAILS

ORGANISATION DETAILS FOR SPONSOR

Nordsjaellands Hospital

Dyrehavevej 29, 3400, Hilleroed, Denmark

CONTACT FOR ASR SUBMISSION

sine wichmann

Nordsjaellands Hospital

Dyrehavevej 29,, 3400, Hilleroed, Denmark

48296773

sine.wichmann@regionh.dk

i The sponsor or co-sponsors **are not** commercial.

i This ASR **is not** a consolidated report following a co-development agreement.

CLINICAL TRIAL DETAILS

[Expand all](#) 

Goal directed fluid removal with furosemide in intensive care patients with fluid overload: a randomised, blinded, placebo-controlled trial (GODIF)

2024-512186-14-00

▼ IMP1: Furosemide / Role: Test ()

Annual safety report details

This is the first sponsor's No

ASR for any of the IMP(s) selected **Submission documents**

If yes, indicate which IMPs

Data lock point 01/01/2025

ASR reporting period 01/01/2024 - 31/12/2024

RSI Updated during the reporting period No

Substantial modification on RSI submitted and approved during the reporting period No

During the reporting period ASR includes None



Annual safety report GODIF trial 2024 

English · ASR Document · **System version 1.00**

Submission date 28/01/2025

· **Version 1** · 28/01/2025

Comment This trial was initiated in 2020 and annual safety reports have been sent to the Danish authorities every year. The trial was transferred to CTIS in October 2024. The last annual

safety report sent to Danish authorities covered the year 2023.
For that reason, the annual safety report for the year 2024 is
now reported.

I, on behalf of the sponsor, confirm that the:

1. Information provided is complete
 2. Attached documents contain an accurate account of the information available
 3. The Sponsor, Nordsjaellands Hospital, declares that the Annual Safety Report is prepared and hereby submitted to the Agency in accordance with Article 43 of Regulation (EU) No 536/2014 and all other applicable legal provisions.
- RSI Document/.s (Old and new version where applicable)
- I agree with the above statements

[Help](#) · [Sitemap](#) · [Contact](#) · [EMA public website](#) · [HMA Intranet](#) · [Legal](#)

2021 EMA Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands

An agency of the European Union 

Software version 1.0.47.1